NCT00813306 - 14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2008

Study Completion Date

November 30, 2009

Conditions

Reflux Episodes

Interventions

DRUG

AZD2066

13 mg oral solution, 1 single dose

DRUG

Placebo

Oral solution, 1 single dose

DRUG

AZD2066

Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose

DRUG

AZD2066

Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose

DRUG

Placebo

Oral solution, 1 single dose

Trial Locations (1)

Research site, Amsterdam